SEATTLE, WA (May 19, 2014): Quorum Review IRB, the industry leader in central IRB services, unveils today an improved process for reviewing minimal risk research.
Quorum’s new Expeditable Research Review allows for faster turnaround time of minimal risk protocols: Next day for qualifying minimal risk protocols with no consent forms or participant materials, and four days for those with consent forms and/or participant materials. The service also features a special discounted pricing.
Click here to learn more.
As Quorum Review CEO Cami Gearhart, JD, explains, this service provides a customized approach to research studies that are designed to involve no greater than minimal risk to study subjects. “Our Expeditable Research Review process has been improved to reflect the different nature of minimal risk protocols. Through our updated internal processes, we are able to provide a more efficient review timeline to our clients.”
The service is of notable interest to researchers hoping to engage in observational registry or data collection studies or those involving minimally invasive procedures.
Tags: data collection studies, discounted pricing, Drug Utilisation Studies, DUS, expeditable review, IRB Services, minimal risk, minimal risk protocols, minimally invasive procedures, NIS, Non-Interventional Studies, Observational Registry, Pharmacovigilance, Phase IV, Post-marketing surveillance (PMS), Quorum Review IRB, registry study, Retrospective Chart Review